About Event

Welcome to the 3rd JAK Inhibitors Drug Development Summit

With experienced insights into innovative therapeutic methods and answers to current setbacks, the 3rd JAK Inhibitors Drug Development Summit is the world’s only meeting solely dedicated to assembling leading pharma, innovative biotechs, pioneering academia, and patient-facing clinicians with real-world experience to successfully develop the next generation of JAK inhibitors for dermatology, autoimmunity, and beyond

  • Optimize safety with comprehensive discussion around the JAK class black box warning issued from the ORAL Surveillance study of Tofacitinib
  • Integrate the patient perspective into your JAK inhibitor drug development pipeline decision making to increase likelihood of prescription with fresh insights from the clinic
  • Debate with clinicians and the FDA which indications JAK inhibitors should be employed as a first or second-line option on the basis of your JAKis selectivity, safety profile, and benefit to the patient

As the only industry-led conference dedicated to the unity industry, clinicians, and academia exploring JAK utilization, expect to hear bubbling cross-disciplinary discussions covering a vast expanse of common challenges


60 Attendees
| 5 hours+ of Networking with Industry Peers | Two Interactive Pre-Conference
Workshops
| Exclusive Presentations from 16+ Field Experts 

Accelerate the Growth of Your JAK Inhibitor Drug Pipeline

icon1

Hear directly from Kendall Marcus, Director of Division of Dermatology at the FDA delivering her insights on the JAKi black box warning and leverage her extended 15-minute Q&A to align your JAKi development & prevent costly setbacks downstream

icon2

Investigate how Arcutis Therapeutics, Eli Lilly & Co. & Incyte consider selectivity and integrate these discussions into the safety concerns with fresh insights from the clinic providing crucial awareness of patient feeling towards JAKis to ensure your JAK is destined for commercial success

icon13

Learn fromColumbia University, Kinaset Therapeutics & University of Massachusetts  on how your chosen route of  JAKi delivery will impact safety profiles, reshape your dosing options & alter pricing of your JAK inhibitor

icon4

Capitalize on the JAK inhibitor success stories pouring out of AAD with fresh alopecia areata insights from Jim Cassella of Concert Pharmaceuticals and Angela Christiano of Columbia University

Don't Just Take Our Word, Hear what Our Attendees Have to Say

“The mix of clinical experts from various fields of expertise (oncology, dermatology asthma etc) in combination with scientific leaders holding expertise in drug development of the next generation JAK inhibitors stood out” 
– CEO, AQILION AB 

“Very well organized and a great assembly of speakers” 
– Associate Professor, Icahn School of Medicine at Mount Sinai 

“Efficient, informative and enjoyable” 
– Chief Development Officer, Kinaset Therapeutics